UIMC is a leader in the field of brain tumor research and is committed to providing our patients access to the most innovative treatments and clinical trials. Four years ago, UIMC became the first hospital in the United States to treat a patient using the NovoTTF device, an entirely new cancer treatment approach. Daniel Torres, a UIMC patient, was able to enroll in a clinical trial to study the device against glioblastoma (GBM) tumors, the most aggressive and deadly form of brain cancer.
UIMC is now participating in a phase III clinical study of the NovoTTF device for patients with newly diagnosed glioblastoma tumors. This clinical study will evaluate the safety and efficacy of the device when used in combination with temozolomide, an oral chemotherapy agent. The NovoTTF is a non-invasive device that creates an alternating electric field within the tumor that has the potential to inhibit cell division and slow or reverse tumor growth. The device is intended for continuous home use and is compatible with a patient’s daily activities.
Torres continues to receive his NovoTTF treatment more than four years later.
To enroll in this trial or to find out about other innovative research in the Department of Neurosurgery, contact Research Manager Karriem Watson at 312-355-0334 or email at email@example.com. For more information on the NovoTTF device, please visit www.novocuretrial.com